Atlas Trials

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Clinical trial NCT02245737 · TERMINATED

Trial details

NCT number
NCT02245737
Sponsor
AstraZeneca
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Alzheimer´s Disease
Start date
2014-09-30
Primary completion
2018-10-04
Enrollment
2218

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.